Upregulation Of Long Non-Coding Rna Atp6v0e2-As1 Predicts A Poor Prognosis In Prostate Cancer

Background: Prostate cancer is a common cancer in males. Previous studies had demonstrated more than 90% of the human genome transcribed non-coding RNA. Long non-coding RNAs could regulate many biological processes in human diseases, including epigenetic regulation, RNA splicing, and protein degradation. The present study explored the prognostic value of a novel lncRNA ATP6V0E2-AS1 in prostate cancer (PCa). Method: The TCGA database was used to explore the expression of ATP6V0E2-AS1 in PCa and normal prostate tissues. The expression of ATP6V0E2-AS1 in PCa clinical samples was detected by real-time PCR. Finally, co-expression analysis, together with bioinformatics analysis, was used to research the functions of ATP6V0E2-AS1 in PCa. Results: The present study showed that ATP6V0E2-AS1 was significantly upregulated in PCa tissues. The qRT-PCR assay showed that ATP6V0E2-AS1 was overexpressed in PCa cell lines compared to WPMY-1. Our results also showed that ATP6V0E2-AS1 was upregulated in high pathology stage PCa. Upregulated ATP6V0E2-AS1 was positively correlated with a shorter survival time in PCa patients by analyzing the Kaplan-Meier dataset. Bioinformatics analysis showed that ATP6V0E2-AS1 was involved in protein translation regulation in PCa. Conclusion: We believe this research will provide new ideas for the diagnosis and treatment of prostate cancer.